Chloe Atreya, MD, PhD

Gastrointestinal Oncology UCSF

Our Care Team

Chloe Atreya, MD, PhD

Emily Bergsland, MD

Eric Collisson, MD

Katie Kelley, MD

Andrew Ko, MD

Michael Korn, MD

Margaret Tempero, MD

Katherine Van Loon, MD, MPH

Alan Venook, MD

Chloe Atreya, MD, PhD
Gastrointestinal cancer specialist

Dr. Chloe E. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment.  

Originally from Ann Arbor, MI, she earned a BA in molecular biology and a Certificate in visual art from Princeton University. Dr. Atreya received her medical degree and Ph.D. in pharmacology at Yale University. Subsequently, she completed her internship and residency in internal medicine at University of Washington, Seattle and fellowship in medical oncology at UCSF, where she is now an Assistant Clinical Professor.  

Dr. Atreya is the recipient of numerous prestigious awards, including the American Cancer Society Postdoctoral Fellowship, Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award and Alliance for Clinical Trials in Oncology Foundation Investigator Award. In 2014 she earned a certificate in Advanced Training in Clinical Research from the UCSF Clinical & Translational Science Institute. She is the recipient of a National Cancer Institute/National Institutes of Health K08 Career Development Award for Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models. Dr. Atreya is a member of the American Society of Clinical Oncologists, American Association of Cancer Researchers and Alliance for Clinical Trials in Oncology, Gastrointestinal Committee.  

Selected Publications

  • Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, and Warren RS. PTEN Expression is Consistent in Colorectal Cancer Primaries and Metastases and Associates with Patient Survival. Cancer Medicine, Epub 06/10/2013
  • Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol. 2015 Mar 1;33(7):682-5. doi: 10.1200/JCO.2014.58.9325. Epub 2015 Jan 12. PMID:25584005  
  • Kelley RK, Atreya CE, Venook AP and Febbo PG. Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time? (2012) J Natl Compr Canc Netw. Commentary. 10(3):303-9. PMID: 22393192.
  • Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ.Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15;136(8):1967-75. doi: 10.1002/ijc.29225. Epub 2014 Sep 29. PMID:25242168